NF-κB is one of the best-known inflammatory transcription factors in biology. When activated, it moves into the nucleus and turns on a broad program of inflammatory gene expression. That includes cytokines, adhesion molecules, enzymes, and many of the other signals that define an active inflammatory state.

It is called a master switch because it sits upstream of so many downstream outcomes. If NF-κB activation is excessive or prolonged, the whole inflammatory program can stay elevated longer than the tissue actually needs.

In resting cells, NF-κB is typically held inactive in the cytoplasm by IκB proteins. When pro-inflammatory signals arrive, IKK phosphorylates IκB, marking it for degradation. Once IκB is removed, NF-κB is free to translocate into the nucleus and activate transcription.

That sequence — IKK activation, IκB removal, nuclear NF-κB signaling — is the backbone of many inflammatory diagrams because it describes how the signal is released and translated into gene output.

KPV is studied because it appears to suppress NF-κB-related inflammatory signaling without relying on classical melanocortin receptor activation. That gives researchers a compact way to study whether damping the transcriptional control layer can calm inflammatory output across gut, skin, and immune models.

NF-κB is not always bad. Acute inflammatory signaling is essential for host defense and repair. The research question is usually about excessive or mis-timed activation, not about eliminating inflammation entirely.